Organism: Homo sapiens
Gene: 39437_at
Selected probe(set): 211975_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39437_at (211975_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-1.8294964
Number of Samples:5 / 6

Experimental	colorectal adenoma study 2
	Laser microdissected human adenoma sample.
Control	normal colon tissue
	Laser microdissected human colonic epithelial cells sample.

Relative Expression (log2-ratio):1.6246481
Number of Samples:2 / 5

Experimental	kidney transplantation study 15 (8 week)
	CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal monocyte (CD14+) sample
	CD14+ monocyte samples derived from healthy control subjects.

Relative Expression (log2-ratio):1.6036873
Number of Samples:2 / 3

Experimental	esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; metastatic)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control	esophagus cancer study 1 (PDX; squamous cell carcinoma, NOS; primary)
	Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the oesophagus (subcutaneously implanted).

Relative Expression (log2-ratio):-1.5399122
Number of Samples:2 / 3

Experimental	brefeldin A study 1 (0.5ug/ml; p53HCT116)
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control	untreated p53HCT116 cell sample
	Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Relative Expression (log2-ratio):-1.4950371
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (novicida)
	Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):-1.431366
Number of Samples:2 / 4

Experimental	R547 study 1 (24h)
	Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control	vehicle (DMSO) treated DU145 cell sample
	Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

Relative Expression (log2-ratio):-1.4138765
Number of Samples:3 / 4

Experimental	expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
	Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.
Control	expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary)
	Primary tumor tissue samples obtained from the ovary of patients with endometrioid and papillary serous adenocarcinoma.

Relative Expression (log2-ratio):-1.4035387
Number of Samples:3 / 3

Experimental	succinate dehydrogenase B depletion study 1 (siRNA)
	Hep3B cells stably transfected with short hairpin vectors containing an siRNA directed to the subunit B of the succinate dehydrogenase.
Control	control siRNA transfected Hep3B cell sample
	Hep3B cells stably transfected with empty siRNA expression vector (pU6).

Relative Expression (log2-ratio):1.3737688
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):1.331563
Number of Samples:5 / 2

Experimental	expO kidney cancer study 1 (renal cell carcinoma, NOS; primary)
	Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS).
Control	expO kidney cancer study 1 (neoplasm, malignant; primary)
	Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.